Earnings Update: Abbott Laboratories (NYSE:ABT) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts
Earnings Update: Abbott Laboratories (NYSE:ABT) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts
Abbott Laboratories (NYSE:ABT) last week reported its latest yearly results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations. It was a credible result overall, with revenues of US$40b and statutory earnings per share of US$3.26 both in line with analyst estimates, showing that Abbott Laboratories is executing in line with expectations. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
雅培實驗室(紐約證券交易所代碼:ABT)上週公佈了最新的年度業績,這是投資者深入了解業務表現是否符合預期的好時機。總體而言,這是一個可信的結果,收入爲400億美元,法定每股收益爲3.26美元,均符合分析師的預期,這表明雅培實驗室的業績符合預期。分析師通常會在每份收益報告中更新他們的預測,我們可以從他們的估計中判斷他們對公司的看法是否發生了變化,或者是否有任何新的問題需要注意。我們認爲,讀者會發現分析師對明年最新(法定)業績後的預測很有趣。
See our latest analysis for Abbott Laboratories
查看我們對雅培實驗室的最新分析
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240126/0-bd33e533cb386d5cf6fa96b6ef590312-0-a41d499651721618cb23e3c3c39fe5df.png/big)
Taking into account the latest results, the most recent consensus for Abbott Laboratories from 20 analysts is for revenues of US$41.9b in 2024. If met, it would imply a reasonable 4.6% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to rise 4.8% to US$3.45. In the lead-up to this report, the analysts had been modelling revenues of US$41.7b and earnings per share (EPS) of US$3.39 in 2024. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
考慮到最新結果,20位分析師對雅培實驗室的最新共識是,2024年的收入爲419億美元。如果得到滿足,這意味着其收入在過去12個月中合理增長了4.6%。預計每股法定收益將增長4.8%,至3.45美元。在本報告發布之前,分析師一直在模擬2024年的收入爲417億美元,每股收益(EPS)爲3.39美元。鑑於他們的估計沒有重大變化,共識分析師似乎沒有在這些結果中看到任何會改變他們對業務看法的內容。
It will come as no surprise then, to learn that the consensus price target is largely unchanged at US$123. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Abbott Laboratories analyst has a price target of US$141 per share, while the most pessimistic values it at US$100.00. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
因此,得知共識目標股價基本保持不變爲123美元也就不足爲奇了。但是,這並不是我們可以從這些數據中得出的唯一結論,因爲一些投資者在評估分析師目標股價時也喜歡考慮估計值的差異。最樂觀的雅培實驗室分析師將目標股價定爲每股141美元,而最悲觀的分析師則將其估值爲100.00美元。這表明估值仍然存在一點差異,但分析師似乎對該股的看法並不完全分歧,好像這可能是成功或失敗一樣。
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that Abbott Laboratories' revenue growth is expected to slow, with the forecast 4.6% annualised growth rate until the end of 2024 being well below the historical 7.9% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 8.0% per year. Factoring in the forecast slowdown in growth, it seems obvious that Abbott Laboratories is also expected to grow slower than other industry participants.
從現在的大局來看,我們可以理解這些預測的方法之一是看看它們如何與過去的業績和行業增長預期相比較。我們要強調的是,雅培實驗室的收入增長預計將放緩,預計到2024年底的年化增長率爲4.6%,遠低於過去五年7.9%的歷史年增長率。相比之下,該行業中其他有分析師覆蓋的公司的收入預計將以每年8.0%的速度增長。考慮到預期的增長放緩,很明顯,雅培實驗室的增長速度預計也將低於其他行業參與者。
The Bottom Line
底線
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Abbott Laboratories' revenue is expected to perform worse than the wider industry. The consensus price target held steady at US$123, with the latest estimates not enough to have an impact on their price targets.
最明顯的結論是,該業務的前景最近沒有重大變化,分析師的收益預測保持穩定,與先前的估計一致。幸運的是,分析師還重申了他們的收入預期,表明收入符合預期。儘管我們的數據確實表明,預計雅培實驗室的收入表現將比整個行業差。共識目標股價穩定在123美元,最新估計不足以對其目標價格產生影響。
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Abbott Laboratories going out to 2026, and you can see them free on our platform here..
話雖如此,公司收益的長期軌跡比明年重要得多。在Simply Wall St,我們有分析師對雅培實驗室到2026年的全方位估計,你可以在我們的平台上免費看到這些估計。
Even so, be aware that Abbott Laboratories is showing 1 warning sign in our investment analysis , you should know about...
即便如此,請注意,雅培實驗室在我們的投資分析中顯示了1個警告信號,您應該知道...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。